S. Baillot-Rudoni

449 total citations
22 papers, 327 citations indexed

About

S. Baillot-Rudoni is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, S. Baillot-Rudoni has authored 22 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in S. Baillot-Rudoni's work include Diabetes Treatment and Management (11 papers), Diabetes Management and Research (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). S. Baillot-Rudoni is often cited by papers focused on Diabetes Treatment and Management (11 papers), Diabetes Management and Research (9 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (8 papers). S. Baillot-Rudoni collaborates with scholars based in France, United States and Belgium. S. Baillot-Rudoni's co-authors include Bruno Vergès, Laurence Duvillard, Jean‐Michel Petit, Benjamin Bouillet, Jean-Paul Paı̈s de Barros, E Florentin, Alexia Rouland, Pascal Degrace, Laurent Demizieux and Philippe Gambert and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Arteriosclerosis Thrombosis and Vascular Biology.

In The Last Decade

S. Baillot-Rudoni

21 papers receiving 316 citations

Peers

Countries citing papers authored by S. Baillot-Rudoni

Since Specialization

Citations

This map shows the geographic impact of S. Baillot-Rudoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Baillot-Rudoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Baillot-Rudoni more than expected).

Fields of papers citing papers by S. Baillot-Rudoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Baillot-Rudoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Baillot-Rudoni. The network helps show where S. Baillot-Rudoni may publish in the future.

Co-authorship network of co-authors of S. Baillot-Rudoni

This figure shows the co-authorship network connecting the top 25 collaborators of S. Baillot-Rudoni. A scholar is included among the top collaborators of S. Baillot-Rudoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Baillot-Rudoni. S. Baillot-Rudoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Glycemic Variability Assessment with a 14-Day Continuous Glucose Monitoring System: When and How Long to Measure MAGE (Mean Amplitude of Glucose Excursion) for Optimal Reliability? 2021 ·Journal of Diabetes Science and Technology ·Bruno Vergès, (unknown), Alexia Rouland, Benjamin Bouillet, S. Baillot-Rudoni, (unknown), (unknown), Jean Michel Petit	11
2	Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression 2021 ·Diabetes Care ·Bruno Vergès, Laurence Duvillard, Jean-Paul Paı̈s de Barros, Benjamin Bouillet, S. Baillot-Rudoni, Alexia Rouland, Jean‐Michel Petit, Pascal Degrace, Laurent Demizieux	32
3	Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients 2020 ·Journal of Diabetes Investigation ·Bruno Vergès, Alexia Rouland, S. Baillot-Rudoni, Marie‐Claude Brindisi, Laurence Duvillard, Isabelle Simoneau, (unknown), (unknown), Benjamin Bouillet	5
4	Whole-exome sequencing identifies the first French MODY 6 family with a new mutation in the NEUROD1 gene 2020 ·Diabetes & Metabolism ·Benjamin Bouillet, (unknown), S. Baillot-Rudoni, (unknown), Thibaud Jouan, Yannis Duffourd, (unknown), (unknown), Patrick Callier	9
5	Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus 2018 ·Arteriosclerosis Thrombosis and Vascular Biology ·Bruno Vergès, Laurence Duvillard, Jean-Paul Paı̈s de Barros, Benjamin Bouillet, S. Baillot-Rudoni, Alexia Rouland, Anne-Laure Sberna, Jean‐Michel Petit, Pascal Degrace, Laurent Demizieux	50
6	Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study 2016 ·Diabetes Technology & Therapeutics ·Sylvie Picard, H. Hanaire, S. Baillot-Rudoni, (unknown), (unknown), Yves Reznik, Bruno Guerci	20
7	Indication, organization, practical implementation and interpretation guidelines for retrospective CGM recording: A French position statement 2015 ·Diabetes & Metabolism ·Michaël Joubert, S. Baillot-Rudoni, Bogdan Catargi, G. Charpentier, (unknown), Sylvia Franc, Bruno Guerci, Isabelle Guilhem, V. Melki, E. Merlen, Alfred Penfornis, Éric Renard, (unknown), Pauline Schaepelynck, A. Sola‐Gazagnes, H. Hanaire	14
8	Assessment of a New Insulin Preparation for Implanted Pumps Used in the Treatment of Type 1 Diabetes 2014 ·Diabetes Technology & Therapeutics ·Pauline Schaepelynck, (unknown), Éric Renard, H. Hanaire, Bruno Guerci, S. Baillot-Rudoni, A. Sola‐Gazagnes, Bogdan Catargi, P. Fontaine, (unknown), (unknown), (unknown), N. Jeandidier, (unknown)	9
9	Is long-acting resveratrol effective on the residual dyslipidemia in statin-treated type 2 diabetic patients? 2014 ·Atherosclerosis ·Bruno Vergès, M.-C. Brindisi, Benjamin Bouillet, (unknown), P. Buffier, S. Baillot-Rudoni, G Vaillant, (unknown), J. Petit	3
10	P1122 Évaluation de l’observance à la mesure en continu du glucose dans le cadre de l’accompagnement du patient diabétique de type 1 traité par pompe à insuline 2013 ·Diabetes & Metabolism ·Bruno Guerci, S. Baillot-Rudoni, (unknown), Yves Reznik, (unknown), (unknown), H. Hanaire	1
11	Chronic Hyperinsulinemia Does Not Increase the Production Rate of High-Density Lipoprotein Apolipoprotein AI 2013 ·Arteriosclerosis Thrombosis and Vascular Biology ·Laurence Duvillard, E Florentin, Frédéric Pont, Jean‐Michel Petit, S. Baillot-Rudoni, Alfred Penfornis, Bruno Vergès	5
12	Real-time continuous glucose monitoring (CGM) integrated into the treatment of type 1 diabetes: Consensus of experts from SFD, EVADIAC and SFE 2012 ·Diabetes & Metabolism ·Pierre‐Yves Benhamou, Bogdan Catargi, (unknown), Bruno Guerci, H. Hanaire, N. Jeandidier, R. Leroy, Laurent Meyer, Alfred Penfornis, (unknown), Éric Renard, S. Baillot-Rudoni, Jean‐Pierre Riveline, Pauline Schaepelynck, A. Sola‐Gazagnes, V. Sulmont, Nadia Tubiana‐Rufi, (unknown), (unknown)	30
13	Endogenous Chronic Hyperinsulinemia Does Not Increase the Production Rate of VLDL Apolipoprotein B: Proof from a Kinetic Study in Patients with Insulinoma 2011 ·The Journal of Clinical Endocrinology & Metabolism ·Laurence Duvillard, E Florentin, Frédéric Pont, Jean‐Michel Petit, S. Baillot-Rudoni, Alfred Penfornis, Bruno Vergès	12
14	P282 - Étude à long terme sur le traitement du diabète de type 2 par pompe à insuline externe 2011 ·Diabetes & Metabolism ·(unknown), S. Baillot-Rudoni, Alfred Penfornis, P. Buffier, (unknown), Benjamin Bouillet, (unknown), J. Petit, Bruno Vergès	0
15	Low HDL-cholesterol: A strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes 2011 ·Diabetes Research and Clinical Practice ·Bruno Vergès, (unknown), S. Baillot-Rudoni, Marie‐Claude Brindisi, A. Poussier, Benjamin Bouillet, Jean‐Michel Petit, Laurence Duvillard	2
16	Non-ultrasound-guided ethanol sclerotherapy for the treatment of thyroid cysts 2011 ·Annales d Endocrinologie ·(unknown), P. Buffier, S. Baillot-Rudoni, Marie‐Claude Brindisi, Benjamin Bouillet, J Petit	2
17	Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes 2009 ·Journal of Lipid Research ·Bruno Vergès, E Florentin, S. Baillot-Rudoni, Jean‐Michel Petit, (unknown), Jean-Paul Paı̈s de Barros, Laurent Lagrost, Philippe Gambert, Laurence Duvillard	26
18	Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes 2008 ·Diabetologia ·Bruno Vergès, E Florentin, S. Baillot-Rudoni, (unknown), Jean‐Michel Petit, Denise Rageot, Philippe Gambert, Laurence Duvillard	21
19	No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients 2006 ·Atherosclerosis ·Laurence Duvillard, E Florentin, S. Baillot-Rudoni, (unknown), (unknown), Jean‐Michel Petit, Jean-Marcel Brun, Philippe Gambert, Bruno Vergès	3
20	Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men 2005 ·Diabetologia ·Laurence Duvillard, E Florentin, (unknown), Jean‐Michel Petit, S. Baillot-Rudoni, (unknown), (unknown), Philippe Gambert, Bruno Vergès	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact